38 min
Alzheimer's & Psychedelics - A New Pathway to Treatment w/Del Potter, PhD Alz In The Fam
-
- Mental Health
New research into psychedelics show promising treatment options for Alzheimer’s and dementia. In Episode 21, the Fair siblings sit down with Dr. Del Potter, PhD – a scientist studying the benefits of psychedelic compounds on brain-related diseases and conditions like dementia, depression and PTSD.
Del Potter, PhD is the chief science officer and founding member of ZBN Research. He received his Ph.D. in Medical Anthropology from UC Berkeley in 1980, specializing in Ethno-psychopharmacology, the phytochemistry, and extraction of psychoactive indigenous botanical pharmacopeia and their cultural significance, and psychiatric anthropology.
Dr. Del Potter shares information on the benefits, availability and future of psychedelic treatment for Alzheimer’s and other dementia related diseases. Potter also discusses the origin of medicinal use of psychedelics.
Research shows that psychedelic compounds have positive effects on targets in the brain that may cause Alzheimer’s. As this research becomes more mainstream, more clinical trials and treatment options are becoming available for people predisposed to Alzheimer’s or dementia and those with mild cognitive impairment.
Dr. Potter also discusses the treatment options available, including a micro dosing approach that minimizes the psychoactive effects but still shows positive results. This could be a promising option for those with moderate to severe Alzheimer’s.
While research is promising, Dr. Potter expresses concerns for the future of medicinal use of psychedelics, as it does become more mainstream and adopted by big pharmaceutical companies.
Overall, the outlook on psychedelic treatment for Alzheimer’s and other brain-related diseases is positive. Dr. Potter shares incredible insights that provide hope for the future of Alzheimer’s research.
To read the article mentioned in Episode 21, go to: https://bit.ly/3szWXRd
If you enjoy the podcast, would you please consider leaving a short review on Apple Podcast/iTunes?
New research into psychedelics show promising treatment options for Alzheimer’s and dementia. In Episode 21, the Fair siblings sit down with Dr. Del Potter, PhD – a scientist studying the benefits of psychedelic compounds on brain-related diseases and conditions like dementia, depression and PTSD.
Del Potter, PhD is the chief science officer and founding member of ZBN Research. He received his Ph.D. in Medical Anthropology from UC Berkeley in 1980, specializing in Ethno-psychopharmacology, the phytochemistry, and extraction of psychoactive indigenous botanical pharmacopeia and their cultural significance, and psychiatric anthropology.
Dr. Del Potter shares information on the benefits, availability and future of psychedelic treatment for Alzheimer’s and other dementia related diseases. Potter also discusses the origin of medicinal use of psychedelics.
Research shows that psychedelic compounds have positive effects on targets in the brain that may cause Alzheimer’s. As this research becomes more mainstream, more clinical trials and treatment options are becoming available for people predisposed to Alzheimer’s or dementia and those with mild cognitive impairment.
Dr. Potter also discusses the treatment options available, including a micro dosing approach that minimizes the psychoactive effects but still shows positive results. This could be a promising option for those with moderate to severe Alzheimer’s.
While research is promising, Dr. Potter expresses concerns for the future of medicinal use of psychedelics, as it does become more mainstream and adopted by big pharmaceutical companies.
Overall, the outlook on psychedelic treatment for Alzheimer’s and other brain-related diseases is positive. Dr. Potter shares incredible insights that provide hope for the future of Alzheimer’s research.
To read the article mentioned in Episode 21, go to: https://bit.ly/3szWXRd
If you enjoy the podcast, would you please consider leaving a short review on Apple Podcast/iTunes?
38 min